Cancer biomarkers that do not cross the translational gap to clinical practice can still further research and drug discovery. In this article, we review several techniques commonly used for cancer biomarker imaging at preclinical stages, as well as recent technological advances.
Triple-negative breast cancer is particularly aggressive, challenging to treat, and accounts for 15-20% of all breast cancers. In this blog, we review a study published in Nature Communications that examines the transforming growth factor-β targetable signaling pathway, its role in malignant cancer progression and immune suppression, and tumor-derived extracellular vesicles as diagnostic and prognostic biomarkers.
The 5th and final episode in the Cutting Edge Conversation series for 2021 features Dr. Morad Nakhleh, Natalie Smith, and Dr. Bhavika Patel as they discuss industry challenges and innovations surrounding biomarkers in life science research and precision medicine
Join Dr. Danyi Wen as she describes a novel drug efficacy test using Patient Derived Xenograft (PDX) samples to measure drug efficacy and identify therapeutic candidates in personalized oncology treatments.